10-K: Northwest Biotherapeutics: Year-End Financials and Operational Update

Northwest Biotherapeutics reports on its 2025 fiscal year, detailing operational progress, financial performance, and ongoing clinical development efforts for its DCVax therapies.

Summary

• Northwest Biotherapeutics, Inc. (NWBO) filed its annual report for the fiscal year ended December 31, 2025, outlining its business operations, financial condition, and future outlook.
• The company is focused on developing personalized immune therapies for cancer, with its lead product, DCVax-L, targeting solid tumor cancers.
• NWBO completed a Phase III trial for DCVax-L for Glioblastoma multiforme (GBM) and submitted a Marketing Authorization Application (MAA) in the UK in December 2023, with the review process ongoing.
• The company also advanced its DCVax-Direct product for inoperable solid tumors, completing a Phase I trial.
• Financially, NWBO reported a net loss of $60.2 million for 2025, an improvement from $83.8 million in 2024, with net cash used in operations decreasing to $44.8 million from $57.0 million.
• Key operational developments in 2025 included the acquisition of Advent BioServices Ltd. to enhance manufacturing capabilities, progress on developing a Grade C lab at the Sawston, UK facility, and evaluation of US manufacturing sites.
• The company continues to manage its liquidity through equity and debt financings, acknowledging substantial doubt about its ability to continue as a going concern.
• Legal proceedings against market makers for alleged stock manipulation are ongoing, with discovery in progress.
• A Delaware litigation concerning 2020 option grants was settled in October 2025, involving the cancellation of 17% of challenged options and a $2.25 million payment from insurance carriers.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the persistent going concern warning, significant ongoing losses, and reliance on continuous financing, despite some operational progress.

Positives

• Net loss improved to $60.2 million in 2025 from $83.8 million in 2024.
• Net cash used in operating activities decreased to $44.8 million in 2025 from $57.0 million in 2024.
• Acquisition of Advent BioServices Ltd. completed to enhance manufacturing capacity and efficiency.
• Progress made on developing a Grade C lab at the Sawston, UK facility, expected to triple manufacturing capacity.
• Continued development of DCVax-Direct technology and planning for Phase II trials.
• Successful settlement of Delaware litigation, with insurance carriers contributing $2.25 million.
• Positive progress in the New York market manipulation lawsuit, allowing the case to proceed to discovery.
• Strengthening of the British pound sterling relative to the U.S. dollar resulted in a foreign currency transaction gain of $4.9 million in 2025.

Negatives

• The company continues to incur substantial losses and has a history of recurring operating losses, raising substantial doubt about its ability to continue as a going concern.
• The company relies on ongoing debt and equity financings to fund operations, with no certainty of future availability on acceptable terms.
• Research and development expenses were $28.8 million in 2025, a decrease from $34.9 million in 2024, primarily due to lower stock-based compensation and MAA application costs.
• General and administrative expenses remained high at $32.5 million in 2025, offset by a reduction in D&O insurance premiums but increased by legal expenses.
• The company has not yet generated material revenue from product sales.
• The acquisition of Advent BioServices Ltd. resulted in the recognition of $51.5 million in intangible assets, which will be amortized over their useful lives.
• The company's common stock is considered a penny stock, which may restrict its liquidity and increase transaction costs.
• The company has not declared or paid any cash dividends and does not anticipate doing so in the foreseeable future.

Risks

• The company will need to raise substantial funds on an ongoing basis for operations, clinical trials, and patent portfolio maintenance, and such funding may not be available on acceptable terms.
• The company's auditors have issued a going concern audit opinion, indicating substantial doubt about its ability to continue as a going concern.
• The company's technology is novel and involves complex immune system elements, and may not prove to be effective or may have unforeseen toxicities.
• Clinical trials are expensive, time-consuming, and their outcomes are uncertain; regulatory approval processes are lengthy and uncertain.
• The company relies on third parties for clinical trial management and data collection, which could lead to delays or failures.
• Failure to comply with regulatory requirements could result in fines, suspension of approvals, or other adverse consequences.
• The company's manufacturing operations at the Sawston, UK facility are subject to risks of capacity limitations and supply disruptions.
• Scaling up manufacturing for commercialization presents significant challenges, as the company and its contract manufacturers have limited experience with such processes for living cell products.
• The company faces intense competition from other biotechnology and pharmaceutical companies with significantly greater financial resources.
• The market price of the company's common stock is volatile and can be adversely affected by numerous factors.
• The company's common stock is considered a penny stock, which may make it difficult to sell and may result in decreased liquidity.
• The company's intellectual property rights may be challenged, narrowed, or blocked, and may not provide sufficient commercial protection.
• The company may be subject to product liability claims, and its existing insurance may not cover these claims.
• The company's business activities may be subject to environmental regulatory requirements.
• Collaborations are important to the company's business and could be vulnerable to competition or termination.
• Changes in legislation and regulatory policies or discovery of product-related problems could adversely affect the business.
• The company may be subject to animal rights activism due to its involvement in animal testing.
• Multiple late-stage clinical trials of DCVax-L for GBM may be required before regulatory approval, which could substantially delay commercialization.
• The company may not receive regulatory approvals for its product candidates or may experience delays in obtaining such approvals.
• The company may not obtain or maintain the benefits associated with orphan drug status, including market exclusivity.
• The company may have disputes with its collaborators, which could be costly and time-consuming.
• The company may be exposed to claims or lawsuits that its products infringe patents or other proprietary rights of other parties.
• The company is dependent on the success of its DCVax platform technology, as it does not currently have other technologies that could provide alternative support.

Future Outlook

The company anticipates continued losses in the near future and relies on ongoing equity and debt financings to fund operations. The success of its DCVax products, including obtaining regulatory approval and securing reimbursement, is critical for future commercialization and financial viability. Preparations for Phase II trials of DCVax-Direct are underway as resources permit.

Management Comments

• The Company believes the acquisition of Advent will facilitate efficiencies and scale-up of its manufacturing capacity.
• The Company plans to announce the results of its MAA review when the regulatory review and decision-making is finished.
• The Company continues to receive an ongoing stream of patient requests for compassionate use of DCVax therapies for a variety of cancers.
• Management's concerns about the company's ability to continue as a going concern persist.
• The Company plans to continue its vigorous pursuit of the market manipulation case.

Industry Context

StockSavvy.ai notes that Northwest Biotherapeutics operates in the highly competitive and rapidly evolving biotechnology sector, focusing on personalized immune therapies for cancer. The company faces significant challenges related to clinical trial costs, regulatory hurdles, and the need for substantial ongoing financing, common in this industry. The development of cell-based therapies is a complex and capital-intensive endeavor, with many companies experiencing similar financial pressures and clinical development risks.

Comparison to Industry Standards

• Many biotech companies at a similar stage of development rely heavily on external financing, often through equity or debt issuances, to fund their operations and clinical trials.
• The lengthy and costly process of clinical trials and regulatory approval is a standard challenge across the pharmaceutical and biotechnology industries.
• The need for specialized manufacturing facilities and expertise for cell-based therapies, like DCVax, is a common industry-wide challenge, often leading to reliance on contract manufacturing organizations or significant investment in internal capacity.
• The volatility of stock prices for early-stage biotechnology companies is typical, driven by clinical trial results, regulatory news, and financing events.

Management Changes

Legal Proceedings

• The company is pursuing a market manipulation lawsuit against certain market makers in the United States District Court for the Southern District of New York. Discovery is ongoing, with a fact discovery deadline of August 28, 2026.
• A Delaware litigation concerning 2020 option grants was settled in October 2025, with 17% of challenged options cancelled and a $2.25 million payment from insurance carriers. The court approved the settlement in March 2026.

Related Party Transactions

• The company acquired Advent BioServices Ltd. on October 24, 2025. Prior to the acquisition, Advent was a related party providing contract services. Linda Powers, the Company's Chairperson and CEO, was the controlling member of the Seller (Toucan Holdings LLC).
• The acquisition consideration included a cash purchase price and payment for outstanding accounts payable due from the Company to Advent.
• Prior to the acquisition, the company had various service contracts and statements of work with Advent BioServices for product development and manufacturing.

Stakeholder Impact

• Shareholders may experience continued stock price volatility and potential dilution from future financings.
• Creditors and noteholders are exposed to the company's ability to meet its debt obligations, which is tied to its ability to secure future funding.
• Employees may be impacted by the company's ongoing financial challenges and the need for continued fundraising.
• Patients seeking access to DCVax therapies may be affected by the pace of clinical development and regulatory approvals.

Next Steps

• Continue active engagement in the MAA review process with the UK's MHRA.
• Work on preparations for Phase II trials of DCVax-Direct as resources permit.
• Continue development of the Sawston, UK facility, including the Grade C lab.
• Pursue clinic arrangements or collaborations in the UK for dedicated leukapheresis capacity.
• Identify and finalize collaboration for a second source of DCVax production capacity.
• Continue evaluation of US manufacturing facilities and hiring of specialized personnel.
• Explore potential for expanded access/compassionate use programs in the US.
• Continue internal testing of immune booster agents for enhanced DCVax products.
• Develop arrangements for clinical trials of in-licensed technologies.
• Continue vigorous pursuit of the market manipulation lawsuit in New York.

Key Dates

Recommendation

While the company shows some operational progress and improved financial metrics, the persistent going concern warning, substantial ongoing losses, and heavy reliance on future financing make it a high-risk investment. The potential for regulatory approval of DCVax-L offers upside, but the path to profitability is long and uncertain. A 'hold' recommendation reflects the balance between speculative potential and significant financial and operational risks.

Keywords

Northwest Biotherapeutics, NWBO, DCVax-L, DCVax-Direct, Glioblastoma multiforme, GBM, Biotechnology, Cancer therapy, Immune therapy, Clinical trials, SEC filing, 10-K, Annual Report, Advent BioServices, Manufacturing, Regulatory approval, Market manipulation lawsuit